Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation

Authors: James Chih‐Hsin Yang, Shirish M. Gadgeel, Lecia VanDam Sequist, Chien-Liang Wu, Vassiliki A. Papadimitrakopoulou, Wu‐Chou Su, Joseph Fiore, Sanatan Saraf, Harry Raftopoulos, Amita Patnaik - Journal of Thoracic Oncology 2018 cited by 183